Lyon Street Capital’s Eledon Pharmaceuticals ELDN Stock Holding History

Lyon Street Capital’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,011	Closed	-$421K	–	49
2018 Q3	$421K	Sell	5,011 -10,733	-68%	-$1.1M	0.26%	43
2018 Q2	$1.98M	Sell	15,744 -3,085	-16%	-$319K	0.71%	40
2018 Q1	$1.71M	Hold	18,829	–	–	0.55%	44
2017 Q4	$1.38M	Buy	18,829 +9,519	+102%	+$719K	0.46%	47
2017 Q3	$873K	Buy	9,310 +7,045	+311%	+$585K	0.34%	54
2017 Q2	$238K	Buy	+2,265	New	+$231K	0.1%	52

Other funds holding ELDN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CSPIA

Cary Street Partners Investment Advisory Richmond, Virginia $494M AUM 27.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lyon Street Capital's ELDN Position: Q4 2018 in Review

Lyon Street Capital sold out of Eledon Pharmaceuticals (ELDN) in Q4 2018, closing a stake of 5,011 shares — an estimated $421K sold.

Lyon Street Capital first reported a position in ELDN in Q2 2017 and held it in 6 quarters. The position peaked at $1.98M in Q2 2018. 16 funds tracked by Wall St. Rank hold ELDN as of Q4 2018.

Lyon Street Capital reported no remaining Eledon Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Lyon Street Capital sold 5,011 Eledon Pharmaceuticals shares in Q4 2018, an estimated $421K.
Lyon Street Capital first reported a position in Eledon Pharmaceuticals in Q2 2017 and held it in 6 quarters.
Lyon Street Capital's Eledon Pharmaceuticals position peaked at $1.98M in Q2 2018.
16 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2018.

Based on Lyon Street Capital's 13F filing for Q4 2018, filed 14 Feb 2019.